213,512 Shares in Revvity, Inc. (NYSE:RVTY) Bought by National Pension Service

National Pension Service acquired a new stake in Revvity, Inc. (NYSE:RVTY) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 213,512 shares of the company’s stock, valued at approximately $23,339,000.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. acquired a new stake in shares of Revvity during the 3rd quarter valued at about $1,579,487,000. Ceredex Value Advisors LLC acquired a new stake in Revvity in the fourth quarter valued at approximately $108,353,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of Revvity in the fourth quarter valued at approximately $80,818,000. Swiss National Bank acquired a new position in shares of Revvity during the 4th quarter worth approximately $42,434,000. Finally, Sumitomo Mitsui Trust Holdings Inc. purchased a new position in shares of Revvity during the 4th quarter valued at approximately $33,568,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on RVTY shares. KeyCorp upped their price objective on shares of Revvity from $110.00 to $126.00 and gave the stock an “overweight” rating in a research report on Friday, February 2nd. Robert W. Baird raised their price target on shares of Revvity from $126.00 to $127.00 and gave the company an “outperform” rating in a research note on Tuesday, April 30th. Raymond James boosted their price objective on Revvity from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Friday, February 2nd. UBS Group downgraded Revvity from a “buy” rating to a “neutral” rating and raised their target price for the company from $105.00 to $125.00 in a research report on Tuesday, January 16th. Finally, Stifel Nicolaus boosted their price target on Revvity from $95.00 to $110.00 and gave the stock a “hold” rating in a research report on Friday, February 2nd. Six research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Revvity has a consensus rating of “Moderate Buy” and a consensus target price of $118.17.

Revvity Trading Up 0.5 %

Shares of NYSE RVTY traded up $0.48 during trading on Thursday, hitting $103.31. 138,166 shares of the company were exchanged, compared to its average volume of 832,665. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.92 and a current ratio of 2.23. Revvity, Inc. has a 12-month low of $79.50 and a 12-month high of $131.96. The company has a fifty day moving average price of $104.39 and a 200-day moving average price of $101.28. The firm has a market capitalization of $12.76 billion, a PE ratio of 84.99, a P/E/G ratio of 2.62 and a beta of 1.09.

Revvity (NYSE:RVTY) last posted its earnings results on Monday, April 29th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.94 by $0.04. The company had revenue of $649.90 million for the quarter, compared to analyst estimates of $646.83 million. Revvity had a net margin of 5.49% and a return on equity of 7.37%. Revvity’s revenue was down 3.7% on a year-over-year basis. During the same period in the previous year, the business posted $1.01 EPS. As a group, equities research analysts expect that Revvity, Inc. will post 4.66 EPS for the current year.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 9th. Shareholders of record on Friday, July 19th will be paid a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, July 19th. This represents a $0.28 annualized dividend and a yield of 0.27%. Revvity’s dividend payout ratio (DPR) is 23.14%.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.